Charlotte Hubbert

Galileo Biosystems, Inc. is a preclinical stage company developing novel products to address inflammatory skin disease needs.

entrinsic bioscience (EBS) combines its proprietary IP platform and discovery engine to deliver next generation functional ingredients and Active Pharmaceutical Ingredients (APIs) designed to address multiple consumer health conditions and serious disease states. EBS was the first to discover that precise, patented combinations of small molecule amino acids can modulate targeted Epithelial Transmembrane Proteins (ETPs) via cell signaling. Through proprietary bio-mapping and electrophysiology techniques, EBS’ platform harnesses the body’s natural signaling mechanisms to protect, maintain, and restore health and wellness across a range of GI, respiratory, and skin conditions. Recent partnerships include leading OTC consumer health companies, the world’s largest CPG company, and a category leading global functional beverage company. EBS’ first commercialized product, enterade Advanced Oncology formula, is an oncology supportive care product clinically proven to significantly reduce the side effects of chemotherapy and radiation treatment. It has been used successfully by over 40,000 patients. For more information, please visit us at www.entrinsicbioscience.com

Lodo Therapeutics discovers and develops novel therapeutics addressing "undruggable" targets with high unmet need by applying its proprietary platform to tap the vast collections of undiscovered molecules encoded in environmental microbial DNA. These drug-like molecules span an enormous range of structural diversity and their biological relevance has been optimized by a billion years of evolution. Lodos proprietary platform leverages breakthroughs in next-generation sequencing, artificial intelligence/machine learning and synthetic biology to increase the speed and efficiency of natural products drug discovery by orders of magnitude. Following successful initial collaborations with two global partners, Lodo is developing an internal pipeline initially focusing on oncology drugs and is expanding its partnering activities in a range of indications

Sera Prognostics is a leading proteomic and bioinformatics company dedicated to improving the lives of women and babies through precision biomarker-based tests designed to enhance pregnancy care. Our vision is to deliver pivotal information to physicians early in pregnancy to help them to improve the health of their patients and reduce costs of healthcare delivery. The PreTRM® Test reports to a physician the individualized risk of premature birth, enabling earlier proactive interventions in patients with higher risk. Were also developing a robust pipeline of innovative tests focused on other complications of pregnancy, including preeclampsia, gestational diabetes, growth restriction, and others. Learn more about our values, culture, and open positions on our website.

Sera Prognostics is a leading proteomic and bioinformatics company dedicated to improving the lives of women and babies through precision biomarker-based tests designed to enhance pregnancy care. Our vision is to deliver pivotal information to physicians early in pregnancy to help them to improve the health of their patients and reduce costs of healthcare delivery. The PreTRM® Test reports to a physician the individualized risk of premature birth, enabling earlier proactive interventions in patients with higher risk. Were also developing a robust pipeline of innovative tests focused on other complications of pregnancy, including preeclampsia, gestational diabetes, growth restriction, and others. Learn more about our values, culture, and open positions on our website.

Synlogic is a clinical-stage biotechnology company developing a new class of biotherapeutics through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU) and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria (EH), and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic also has research collaborations established with Roche and Ginkgo Bioworks.

Synlogic is a clinical-stage biotechnology company developing a new class of biotherapeutics through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU) and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria (EH), and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic also has research collaborations established with Roche and Ginkgo Bioworks.

Alder is a biopharmaceutical company committed to transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. The company’s mission is to forever change migraine treatment and give people with migraine their lives back. Alder knows the physical and emotional toll migraine can take not just on the individual but also those who care for them. In fact, some of our employees suffer from migraine themselves. To Alder, people with migraine are not “nameless” subjects or data points, but friends, family, and others whose stories motivate Alder to do its best work. The team’s insight into the needs of migraine patients has enabled us to leverage our monoclonal antibody expertise to design best-in-class therapies.

Seed, early stage and acceleration stage investor and partner for founders. Investing for over 30 years in machine learning, AI, marketplaces, infra, devops, and biotech startups.

City of Hopes mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and treatment facilities in Atlanta, Chicago and Phoenix. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHope™.

AIF invests in healthcare technology and innovation to scale next-generation solutions across care delivery, services, and digital health, transforming how behavioral health, mental health, autism, and associated complex chronic conditions are treated

Galileo Biosystems, Inc. is a preclinical stage company developing novel products to address inflammatory skin disease needs.

entrinsic bioscience (EBS) combines its proprietary IP platform and discovery engine to deliver next generation functional ingredients and Active Pharmaceutical Ingredients (APIs) designed to address multiple consumer health conditions and serious disease states. EBS was the first to discover that precise, patented combinations of small molecule amino acids can modulate targeted Epithelial Transmembrane Proteins (ETPs) via cell signaling. Through proprietary bio-mapping and electrophysiology techniques, EBS’ platform harnesses the body’s natural signaling mechanisms to protect, maintain, and restore health and wellness across a range of GI, respiratory, and skin conditions. Recent partnerships include leading OTC consumer health companies, the world’s largest CPG company, and a category leading global functional beverage company. EBS’ first commercialized product, enterade Advanced Oncology formula, is an oncology supportive care product clinically proven to significantly reduce the side effects of chemotherapy and radiation treatment. It has been used successfully by over 40,000 patients. For more information, please visit us at www.entrinsicbioscience.com